Brazil is phasing out the use of similares, which are knockoffs of branded drugs that have not demonstrated bioequivalence to the corresponding brand. When similares are gone, the generic-drug market in Brazil will be a lot like the one in the US.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.